Bio-Path (NASDAQ: BPTH) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Bio-Path and Brainstorm Cell Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Path 0 0 2 0 3.00
Brainstorm Cell Therapeutics 0 0 1 0 3.00

Bio-Path currently has a consensus price target of $1.75, indicating a potential upside of 533.83%. Brainstorm Cell Therapeutics has a consensus price target of $9.00, indicating a potential upside of 121.67%. Given Bio-Path’s higher possible upside, analysts clearly believe Bio-Path is more favorable than Brainstorm Cell Therapeutics.

Volatility & Risk

Bio-Path has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Valuation and Earnings

This table compares Bio-Path and Brainstorm Cell Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Bio-Path $10,000.00 3,130.70 -$6.75 million ($0.07) -3.94
Brainstorm Cell Therapeutics N/A N/A -$4.98 million ($0.31) -13.10

Brainstorm Cell Therapeutics has higher revenue, but lower earnings than Bio-Path. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Path and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bio-Path N/A -128.84% -118.51%
Brainstorm Cell Therapeutics N/A -76.45% -59.84%

Insider & Institutional Ownership

11.6% of Bio-Path shares are held by institutional investors. Comparatively, 12.9% of Brainstorm Cell Therapeutics shares are held by institutional investors. 11.2% of Bio-Path shares are held by company insiders. Comparatively, 24.7% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bio-Path Company Profile

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.